Slow and opaque decisions during Covid-19 crisis put the spotlight on India’s drug regulator: On April 3, biotech startup Bione Ventures Private Limited announced the launch of its “break-through…simple point-of-care home screening kit”. These rapid antibody kits, the company said, had been sourced from “worldwide” partners and had received approval from the “requisite regula-tory authorities”. With the IC MR’s test kits starting to run scarce and testing having recently opened up to the private sector, the announcement invoked media interest. However, rapid tests, which look for disease-fighting antibodies as opposed to the virus itself, could give misleading re-sults and are not reliable diagnostic kits as the company seemed to be marketing them as.Read more here.
or reload the browserDisable in this text fieldEditEdit in GingerEdit in Ginger×
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in